Gilead stock

Gilead Sciences, Inc. (NASDAQ: GILD) released first quarter 2015 earnings on April 30. High revenues pointed to the success of Gilead’s blockbuster hepatitis C therapies; Sovaldi and Harvoni. Analysts had estimated that Gilead would post diluted earnings per share of $2.32 for the quarter...